{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":16,"n_cols":5,"rows_kept":16,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[5,2,5,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[11,2,11,3],[12,2,12,3],[15,2,15,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910583071203321"]
[null,null,"Autore",null,"Galili Uri"]
[null,null,"Titolo",null,"The natural anti-gal antibody as foe turned friend in medicine / / Uri Galili"]
[null,null,"Pubbl/distr/stampa",null,"London, England : , : Academic Press, , 2018"]
[{"$nulls":4},"©2018"]
[null,null,"ISBN",null,"0-12-813363-5"]
[{"$nulls":4},"0-12-813362-7"]
[null,null,"Descrizione fisica",null,"1 online resource (301 pages) : illustrations (some color)"]
[null,null,"Disciplina",null,"612.11822"]
[null,null,"Soggetti",null,"Antigen-antibody reactions"]
[{"$nulls":4},"Antigens - Analysis"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Includes index."]
[null,null,"Nota di contenuto",null,"Anti-gal in humans and its antigen the [alpha]-gal epitope -- Why do we produce anti-gal -- Anti-gal comprises most of anti-blood group b antibodies -- Anti-gal interaction with Trypansoma, Leishmania, and Plasmodium parasites -- Anti-gal b cells are tolerized by a [alpha]-gal epitopes in the absence of t cell help -- Anti-gal and other immune barriers in xenotransplantation -- Anti-gal IgE mediates allergies to red meat -- Anti-gal and autoimmunity -- Anti-gal-mediated amplification of viral vaccine efficacy -- Cancer immunotherapy by anti-gal-mediated in situ conversion of tumors into autologous vaccines -- Anti-gal as cancer cell destroying antibody and as antibiotics targeted by [alpha]-gal bifunctional molecules -- Acceleration of wound and burn healing by anti-gal/[alpha]-gal nanoparticles interaction -- Anti-gal and anti-non gal antibodies in regeneration of extracellular matrix bio-implants -- Post infarction regeneration of ischemic myocardium by intramyocardial injection of [alpha]-gal nanoparticles -- Regeneration of injured spinal cord and peripheral nerves by [alpha]-gal nanoparticles -- Inhalation of [alpha]-gal/sialic acid liposomes for decreasing influenza virus infection."]